局灶节段性肾小球硬化组织学变异型与肾脏结局:基于肾病综合征、免疫抑制和蛋白尿缓解的分析
该研究基于日本全国肾活检登记数据,分析304例活检确诊的FSGS患者(173例肾病综合征,131例非肾病综合征),按Columbia分型比较5年内eGFR下降30%或进展至终末期肾病的复合终点。结果显示各变异型间结局无显著差异,但蛋白尿缓解与更好的肾脏预后相关(调整HR 0.19,95%CI 0.10-0.34)。
要点
- FSGS各组织学变异型间5年肾脏结局无显著差异。
- 蛋白尿缓解(<0.3 g/天)与更好的肾脏预后独立相关。
- 肾病综合征较非肾病综合征有边际更好的结局趋势。
核心结论
- FSGS组织学变异型本身可能对5年肾脏结局无显著影响,而蛋白尿缓解可预测任何变异型的更好肾脏预后。
研究设计与样本
- 回顾性队列研究,纳入2010至2013年日本全国肾活检登记中304例活检确诊FSGS患者(173例肾病综合征,131例非肾病综合征)。
主要发现
- 变异型分布:非特指型48%(n=145)、尖端型19%(n=57)、肾门型15%(n=47)、细胞型13%(n=40)、塌陷型5%(n=15)。
- 87例(29%)发生主要结局事件,各变异型间结局无显著差异,亚组分析结果相似。
- 蛋白尿缓解与更好结局相关,调整HR 0.19(95%CI 0.10-0.34)。
- 肾病综合征与非肾病综合征相比,调整HR 0.50(95%CI 0.25-1.01),为边际关联。
临床怎么用
- 临床应致力于实现FSGS患者蛋白尿缓解(<0.3 g/天),无论组织学变异型,以改善肾脏预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The associations of focal segmental glomerulosclerosis (FSGS) histological variants with renal outcomes have rarely been investigated comprehensively by clinically relevant subgroups in this modern age. METHODS: Data on 304 (173 nephrotic and 131 non-nephrotic) patients with biopsy-confirmed FSGS from 2010 to 2013 were analyzed using the Japanese nationwide renal biopsy registry. The primary outcome was a composite of a 30% decline in estimated glomerular filtration rate or progression to end-stage kidney disease 5 years from the biopsy. We compared outcomes of FSGS variants according to the Columbia classification using survival analyses. Subgroup analyses were performed based on nephrotic syndrome (NS), immunosuppression and proteinuria remission (PR; proteinuria <0.3 g/day) during follow-up. Additionally, associations of NS, immunosuppression and PR with outcomes were examined for each variant. RESULTS: The distribution of variants was 48% (n = 145) FSGS not otherwise specified, 19% (n = 57) tip, 15% (n = 47) perihilar, 13% (n = 40) cellular and 5% (n = 15) collapsing. The outcome event occurred in 87 patients (29%). No significant differences in the outcome were found among the variants. Subgroup analyses yielded similar results. However, there was a trend toward improved outcome in patients with PR irrespective of variants [hazard ratio adjusted for histological variant and potential confounders (adjusted HR) 0.19 (95% confidence interval 0.10-0.34)]. NS was marginally associated with better outcome compared with non-NS [adjusted HR 0.50 (95% confidence interval 0.25-1.01)]. CONCLUSIONS: FSGS variants alone might not have significant impacts on the renal outcome after 5 years, while PR could be predictive of improved renal prognosis for any variant. Specific strategies and interventions to achieve PR for each variant should be implemented for better renal outcomes.
引用
- Kawaguchi T, Imasawa T, Kadomura M, et al. Focal segmental glomerulosclerosis histologic variants and renal outcomes based on nephrotic syndrome, immunosuppression and proteinuria remission. Nephrol Dial Transplant. 2022. PMID: 34499164. doi:10.1093/ndt/gfab267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。